|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MEOX2 |
Gene summary for MEOX2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MEOX2 | Gene ID | 4223 |
| Gene name | mesenchyme homeobox 2 | |
| Gene Alias | GAX | |
| Cytomap | 7p21.2 | |
| Gene Type | protein-coding | GO ID | GO:0001525 | UniProtAcc | P50222 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4223 | MEOX2 | ATC12 | Human | Thyroid | ATC | 1.68e-15 | 3.43e-01 | 0.34 |
| 4223 | MEOX2 | ATC13 | Human | Thyroid | ATC | 1.51e-42 | 1.09e+00 | 0.34 |
| 4223 | MEOX2 | ATC4 | Human | Thyroid | ATC | 5.40e-19 | 4.05e-01 | 0.34 |
| 4223 | MEOX2 | ATC5 | Human | Thyroid | ATC | 5.50e-43 | 1.15e+00 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000166731 | Thyroid | ATC | ameboidal-type cell migration | 228/6293 | 475/18723 | 3.72e-11 | 1.22e-09 | 228 |
| GO:001063131 | Thyroid | ATC | epithelial cell migration | 169/6293 | 357/18723 | 4.21e-08 | 7.69e-07 | 169 |
| GO:009013031 | Thyroid | ATC | tissue migration | 171/6293 | 365/18723 | 8.55e-08 | 1.47e-06 | 171 |
| GO:009013231 | Thyroid | ATC | epithelium migration | 169/6293 | 360/18723 | 8.57e-08 | 1.47e-06 | 169 |
| GO:006053724 | Thyroid | ATC | muscle tissue development | 181/6293 | 403/18723 | 1.27e-06 | 1.62e-05 | 181 |
| GO:001063231 | Thyroid | ATC | regulation of epithelial cell migration | 137/6293 | 292/18723 | 1.44e-06 | 1.77e-05 | 137 |
| GO:001470622 | Thyroid | ATC | striated muscle tissue development | 168/6293 | 384/18723 | 1.91e-05 | 1.73e-04 | 168 |
| GO:004354231 | Thyroid | ATC | endothelial cell migration | 127/6293 | 279/18723 | 2.14e-05 | 1.91e-04 | 127 |
| GO:000751716 | Thyroid | ATC | muscle organ development | 139/6293 | 327/18723 | 4.45e-04 | 2.64e-03 | 139 |
| GO:001059431 | Thyroid | ATC | regulation of endothelial cell migration | 102/6293 | 232/18723 | 6.17e-04 | 3.51e-03 | 102 |
| GO:004001316 | Thyroid | ATC | negative regulation of locomotion | 160/6293 | 391/18723 | 1.36e-03 | 7.07e-03 | 160 |
| GO:003033616 | Thyroid | ATC | negative regulation of cell migration | 142/6293 | 344/18723 | 1.64e-03 | 8.22e-03 | 142 |
| GO:00600211 | Thyroid | ATC | roof of mouth development | 42/6293 | 85/18723 | 1.83e-03 | 9.02e-03 | 42 |
| GO:005127117 | Thyroid | ATC | negative regulation of cellular component movement | 150/6293 | 367/18723 | 1.99e-03 | 9.54e-03 | 150 |
| GO:200014617 | Thyroid | ATC | negative regulation of cell motility | 147/6293 | 359/18723 | 2.01e-03 | 9.60e-03 | 147 |
| GO:00487368 | Thyroid | ATC | appendage development | 76/6293 | 172/18723 | 2.41e-03 | 1.12e-02 | 76 |
| GO:00601738 | Thyroid | ATC | limb development | 76/6293 | 172/18723 | 2.41e-03 | 1.12e-02 | 76 |
| GO:006053814 | Thyroid | ATC | skeletal muscle organ development | 71/6293 | 166/18723 | 8.39e-03 | 3.22e-02 | 71 |
| GO:000751913 | Thyroid | ATC | skeletal muscle tissue development | 66/6293 | 155/18723 | 1.20e-02 | 4.27e-02 | 66 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| MEOX2 | INCAF | Cervix | ADJ | S100A3,SCN4B,HHIP-AS1, etc. | 9.22e-02 |  |
| MEOX2 | FIB | Cervix | N_HPV | S100A3,SCN4B,HHIP-AS1, etc. | 0.00e+00 |  |
| MEOX2 | PVA | Liver | Cirrhotic | ZFP28,VEGFC,PLN, etc. | 4.22e-01 |  |
| MEOX2 | SMC | Liver | Healthy | ZFP28,VEGFC,PLN, etc. | 5.30e-02 |  |
| MEOX2 | PERI | Stomach | GC | STEAP4,CFH,CPE, etc. | 5.39e-02 |  |
| MEOX2 | PERI | Thyroid | goiters | EGFR,DYNC1I1,LRP1, etc. | 6.54e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MEOX2 | SNV | Missense_Mutation | c.572G>A | p.Arg191Lys | p.R191K | P50222 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-AN-A0FK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| MEOX2 | SNV | Missense_Mutation | c.836N>T | p.Thr279Ile | p.T279I | P50222 | protein_coding | tolerated_low_confidence(0.1) | benign(0.021) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MEOX2 | SNV | Missense_Mutation | c.794N>A | p.Gly265Glu | p.G265E | P50222 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A18L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| MEOX2 | SNV | Missense_Mutation | novel | c.442N>A | p.Asp148Asn | p.D148N | P50222 | protein_coding | deleterious(0.03) | benign(0.355) | TCGA-E2-A1LE-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | herceptin | PD |
| MEOX2 | SNV | Missense_Mutation | c.151N>A | p.Ala51Thr | p.A51T | P50222 | protein_coding | tolerated(0.59) | benign(0) | TCGA-C5-A2M1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| MEOX2 | SNV | Missense_Mutation | novel | c.40N>A | p.Ala14Thr | p.A14T | P50222 | protein_coding | deleterious(0.04) | benign(0.161) | TCGA-C5-A8XJ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
| MEOX2 | SNV | Missense_Mutation | novel | c.470C>T | p.Ala157Val | p.A157V | P50222 | protein_coding | tolerated(0.33) | benign(0) | TCGA-EA-A439-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| MEOX2 | SNV | Missense_Mutation | c.485G>A | p.Arg162Gln | p.R162Q | P50222 | protein_coding | tolerated(0.07) | possibly_damaging(0.788) | TCGA-EK-A2IP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| MEOX2 | SNV | Missense_Mutation | novel | c.40G>A | p.Ala14Thr | p.A14T | P50222 | protein_coding | deleterious(0.04) | benign(0.161) | TCGA-ZX-AA5X-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| MEOX2 | SNV | Missense_Mutation | rs141784602 | c.490N>A | p.Gly164Ser | p.G164S | P50222 | protein_coding | tolerated(1) | benign(0) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |